Dendreon (DNDN) ends its development and supply agreement with GlaxoSmithKline (GSK) on...

|About: Dendreon Corporation (DNDN)|By:, SA News Editor

Dendreon (DNDN) ends its development and supply agreement with GlaxoSmithKline (GSK) on Dendreon's prostate cancer vaccine Provenge, citing "unforeseen delays and implementation difficulties." DNDN shares have plunged nearly 70% after the company withdrew its revenue forecast for Provenge on Aug. 4. DNDN -4.6% premarket.